Drug · DIN 02247600
BOOSTRIX
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 29, 2007; first marketed May 29, 2007.
- Drug Identification Number (DIN)
- 02247600
- Company (DIN owner)
- Glaxosmithkline IncMississauga, Ontario, Canada
- Schedule
- Schedule d
- Dosage form
- Suspension
- Route
- Intramuscular
- Therapeutic class (ATC)
- Other bacterial vaccines J07AX
- Class
- Human
- Record last updated
- June 29, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DIPHTHERIA TOXOID | 2 UNIT | 0.5 ML |
| TETANUS TOXOID | 20 UNIT | 0.5 ML |
| PERTUSSIS TOXOID | 8 MCG | 0.5 ML |
| FILAMENTOUS HAEMAGGLUTININ | 8 MCG | 0.5 ML |
| PERTACTIN | 2.5 MCG | 0.5 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 25, 2006: NOC 8230Supplement to a New Drug Submission (SNDS) · Additional manufacturing facility
- May 16, 2003: NOC 479New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “boostrix”. A notice may cover another product or only some lots: read it to see what it covers.
- BOOSTRIX: Syringes may be cracked in affected lot.October 7, 2022 · Biologic or vaccine · Product quality · Type II